ADVERTISEMENT
Government Payers
Under the Inflation Reduction Act, CMS negotiated lower Medicare Part D prices for 15 drugs with 2027 costs 38%-85% lower than 2024 list prices, but analyses of net prices paid last year show smaller discounts.
Amendments to Germany’s – barely in force – health reform law will be decided after the summer break. The new DRGs payments plan and service groups will be reviewed, but critics fear for the law’s future.
Lilly said prices governments pay in developed countries, including those in Europe, need to increase to make US drug prices lower, rebalancing costs as CEO David Ricks recently advocated.
The new 60-day deadline for striking a deal with the drug industry underscores the challenges the Administration may be having in developing non-voluntary policies to achieve MFN pricing in the US.
An “NHS Innovator Passport” that allows quicker uptake of proven technologies across the national healthcare provider is one of the wins the UK government is looking to score from its new Life Sciences Sector plan. The plan majors on prevention. The medtech industry has given it a cautious welcome.
The UK government’s blueprint to deliver an NHS "fit for the future" was released on July 3.
The NHS 10-Year Plan officially released on July 3 will crystalize NICE’s Rules-Based Pathway – a new concept for medtech evaluation that will come with a guarantee of funding – but only for a select number of products. Government to also introduce “innovator passport” to speed innovation into NHS.
Healthcare product industries await publication of the NHS 10-Year Plan, due out the coming days, which will focus on health generally not just the NHS, UK health secretary Wes Streeting said during a final prelaunch event on 24 June.
Legal experts warn, however, that new Mexican procurement rules are discriminatory and could be challenged in the courts.
Legal experts warn, however, that new Mexican procurement rules are discriminatory and could be challenged in the courts.
The order aims to eliminate the gap between small molecules and biologics in terms of the time to IRA-mandated Medicare negotiations, but pharma’s gain could be offset by other directives.
The first reimbursement reports published by the Spanish health ministry to improve transparency focus on CSL’s Hemgenix, BMS’ Camzyos and Pfizer’s Velsipity.